B-intervention	0	10	Zoledronic
I-intervention	11	15	acid
O	16	29	significantly
O	30	37	reduces
B-condition	38	46	skeletal
I-condition	47	60	complications
O	61	69	compared
O	70	74	with
O	75	82	placebo
O	83	85	in
B-ethinicity	86	94	Japanese
B-eligibility	95	100	women
I-eligibility	101	105	with
I-eligibility	106	110	bone
I-eligibility	111	121	metastases
I-eligibility	122	126	from
I-eligibility	127	133	breast
I-eligibility	134	140	cancer
O	140	141	:
O	142	143	a
O	144	154	randomized
O	154	155	,
O	156	163	placebo
O	163	164	-
O	164	174	controlled
O	175	180	trial
O	180	181	.

O	182	184	To
O	185	196	investigate
O	197	200	the
O	201	209	efficacy
O	210	213	and
O	214	220	safety
O	221	223	of
O	224	234	zoledronic
O	235	239	acid
O	240	243	for
O	244	247	the
O	248	257	treatment
O	258	260	of
O	261	265	bone
O	266	276	metastases
O	277	281	from
O	282	288	breast
O	289	295	cancer
O	295	296	.

O	297	302	Women
O	303	307	with
O	308	312	bone
O	313	323	metastases
O	324	325	(
O	325	326	N
O	327	328	=
B-total-participants	329	332	228
O	332	333	)
O	334	338	were
O	339	347	randomly
O	348	356	assigned
O	357	359	to
O	360	367	receive
O	368	369	4
O	370	372	mg
O	373	383	zoledronic
O	384	388	acid
O	389	390	(
O	390	391	n
O	392	393	=
B-intervention-participants	394	397	114
O	397	398	)
O	399	401	or
B-control	402	409	placebo
O	410	411	(
O	411	412	n
O	413	414	=
B-control-participants	415	418	114
O	418	419	)
O	420	423	via
O	424	426	15
O	426	427	-
O	427	433	minute
O	434	443	infusions
O	444	449	every
O	450	451	4
O	452	457	weeks
O	458	461	for
O	462	463	1
O	464	468	year
O	468	469	.

O	470	473	The
O	474	481	primary
O	482	490	efficacy
O	491	494	end
O	495	500	point
O	501	504	was
O	505	508	the
B-outcome-Measure	509	517	skeletal
I-outcome-Measure	517	518	-
I-outcome-Measure	518	525	related
I-outcome-Measure	526	531	event
I-outcome-Measure	532	533	(
I-outcome-Measure	533	536	SRE
I-outcome-Measure	536	537	)
I-outcome-Measure	538	542	rate
I-outcome-Measure	543	548	ratio
O	549	556	between
O	557	566	treatment
O	567	573	groups
O	573	574	.

O	575	577	An
O	578	581	SRE
O	582	585	was
O	586	593	defined
O	594	596	as
O	597	607	pathologic
O	608	616	fracture
O	616	617	,
O	618	624	spinal
O	625	629	cord
O	630	641	compression
O	641	642	,
O	643	646	and
O	647	656	radiation
O	657	659	or
O	660	667	surgery
O	668	670	to
O	671	675	bone
O	675	676	.

O	677	686	Secondary
O	687	690	end
O	691	697	points
O	698	706	included
B-outcome-Measure	707	717	percentage
I-outcome-Measure	718	720	of
I-outcome-Measure	721	729	patients
I-outcome-Measure	730	734	with
I-outcome-Measure	735	737	at
I-outcome-Measure	738	743	least
I-outcome-Measure	744	747	one
I-outcome-Measure	748	751	SRE
O	751	752	,
B-outcome-Measure	753	757	time
I-outcome-Measure	757	758	-
I-outcome-Measure	758	760	to
I-outcome-Measure	760	761	-
I-outcome-Measure	761	766	first
I-outcome-Measure	767	770	SRE
O	770	771	,
O	772	775	and
B-outcome-Measure	776	784	Andersen
I-outcome-Measure	784	785	-
I-outcome-Measure	785	789	Gill
I-outcome-Measure	790	798	multiple
I-outcome-Measure	798	799	-
I-outcome-Measure	799	804	event
I-outcome-Measure	805	813	analysis
O	813	814	.

O	815	818	The
O	819	822	SRE
O	823	827	rate
O	828	833	ratio
O	834	836	at
O	837	838	1
O	839	843	year
O	844	845	(
O	845	854	excluding
O	855	858	HCM
O	859	862	and
O	863	871	adjusted
O	872	875	for
O	876	881	prior
O	882	890	fracture
O	890	891	)
O	892	895	was
O	896	897	0
O	897	898	.
O	898	900	61
O	901	902	(
O	902	913	permutation
O	914	918	test
O	918	919	;
O	920	921	P
O	922	923	=
O	924	925	.
O	925	928	027
O	928	929	)
O	929	930	,
O	931	941	indicating
O	942	946	that
O	947	957	zoledronic
O	958	962	acid
O	963	970	reduced
O	971	974	the
B-outcome	975	979	rate
I-outcome	980	982	of
I-outcome	983	986	SRE
O	987	989	by
O	990	992	39
O	992	993	%
O	994	1002	compared
O	1003	1007	with
O	1008	1015	placebo
O	1015	1016	.

O	1017	1020	The
O	1021	1031	percentage
O	1032	1034	of
B-outcome	1035	1043	patients
I-outcome	1044	1048	with
I-outcome	1049	1051	at
I-outcome	1052	1057	least
I-outcome	1058	1061	one
I-outcome	1062	1065	SRE
O	1066	1067	(
O	1067	1076	excluding
O	1077	1080	HCM
O	1080	1081	)
O	1082	1085	was
O	1086	1099	significantly
O	1100	1107	reduced
O	1108	1110	by
O	1111	1113	20
O	1113	1114	%
O	1115	1117	by
O	1118	1128	zoledronic
O	1129	1133	acid
O	1134	1135	(
B-iv-bin-percent	1135	1137	29
I-iv-bin-percent	1137	1138	.
I-iv-bin-percent	1138	1139	8
I-iv-bin-percent	1139	1140	%
O	1141	1142	v
B-cv-bin-percent	1143	1145	49
I-cv-bin-percent	1145	1146	.
I-cv-bin-percent	1146	1147	6
I-cv-bin-percent	1147	1148	%
O	1149	1152	for
O	1153	1160	placebo
O	1160	1161	;
O	1162	1163	P
O	1164	1165	=
O	1166	1167	.
O	1167	1170	003
O	1170	1171	)
O	1171	1172	.

O	1173	1183	Zoledronic
O	1184	1188	acid
O	1189	1202	significantly
O	1203	1210	delayed
B-outcome	1211	1215	time
I-outcome	1215	1216	-
I-outcome	1216	1218	to
I-outcome	1218	1219	-
I-outcome	1219	1224	first
I-outcome	1225	1228	SRE
O	1229	1230	(
O	1230	1236	median
B-iv-cont-median	1237	1240	not
I-iv-cont-median	1241	1248	reached
O	1249	1250	v
B-cv-cont-median	1251	1254	364
I-cv-cont-median	1255	1259	days
O	1259	1260	;
O	1261	1264	Cox
O	1265	1275	regression
O	1275	1276	;
O	1277	1278	P
O	1279	1280	=
O	1281	1282	.
O	1282	1285	007
O	1285	1286	)
O	1287	1290	and
O	1291	1298	reduced
O	1299	1302	the
B-outcome	1303	1307	risk
I-outcome	1308	1310	of
I-outcome	1311	1315	SREs
O	1316	1318	by
O	1319	1321	41
O	1321	1322	%
O	1323	1325	in
O	1326	1334	multiple
O	1335	1340	event
O	1341	1349	analysis
O	1350	1351	(
O	1351	1355	risk
O	1356	1361	ratio
O	1362	1363	=
O	1364	1365	0
O	1365	1366	.
O	1366	1368	59
O	1368	1369	;
O	1370	1371	P
O	1372	1373	=
O	1374	1375	.
O	1375	1378	019
O	1378	1379	)
O	1380	1388	compared
O	1389	1393	with
O	1394	1401	placebo
O	1401	1402	.

O	1403	1413	Zoledronic
O	1414	1418	acid
O	1419	1422	was
O	1423	1427	well
O	1428	1437	tolerated
O	1438	1442	with
O	1443	1444	a
B-outcome	1445	1451	safety
I-outcome	1452	1459	profile
O	1460	1467	similar
O	1468	1470	to
O	1471	1478	placebo
O	1478	1479	.

O	1480	1482	No
O	1483	1490	patient
O	1491	1498	treated
O	1499	1503	with
O	1504	1514	zoledronic
O	1515	1519	acid
O	1520	1523	had
B-outcome	1524	1529	grade
I-outcome	1530	1531	3
I-outcome	1532	1534	or
I-outcome	1535	1536	4
I-outcome	1537	1542	serum
I-outcome	1543	1553	creatinine
I-outcome	1554	1562	increase
O	1562	1563	.

O	1564	1574	Zoledronic
O	1575	1579	acid
O	1580	1593	significantly
O	1594	1601	reduced
O	1602	1610	skeletal
O	1611	1624	complications
O	1625	1633	compared
O	1634	1638	with
O	1639	1646	placebo
O	1647	1653	across
O	1654	1662	multiple
O	1663	1666	end
O	1667	1673	points
O	1674	1676	in
O	1677	1685	Japanese
O	1686	1691	women
O	1692	1696	with
O	1697	1701	bone
O	1702	1712	metastases
O	1713	1717	from
O	1718	1724	breast
O	1725	1731	cancer
O	1731	1732	.
